在复发性BALB/c结核小鼠模型中，spectinamide MBX-4888A替代利奈唑胺在Nix-TB方案中的杀菌活性

IF 4.5 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2025-09-30 DOI:10.1128/aac.01183-25

Nathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, Samanthi L Waidyarachchi, Jiuyu Liu, Joel N Rushefsky, Michelle M Butler, Terry Bowlin, Bernd Meibohm, Mercedes Gonzalez-Juarrero, Anne J Lenaerts, Matthew Zimmerman, Richard E Lee, Gregory T Robertson

{"title":"在复发性BALB/c结核小鼠模型中，spectinamide MBX-4888A替代利奈唑胺在Nix-TB方案中的杀菌活性","authors":"Nathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, Samanthi L Waidyarachchi, Jiuyu Liu, Joel N Rushefsky, Michelle M Butler, Terry Bowlin, Bernd Meibohm, Mercedes Gonzalez-Juarrero, Anne J Lenaerts, Matthew Zimmerman, Richard E Lee, Gregory T Robertson","doi":"10.1128/aac.01183-25","DOIUrl":null,"url":null,"abstract":"Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0118325"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.\",\"authors\":\"Nathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, Samanthi L Waidyarachchi, Jiuyu Liu, Joel N Rushefsky, Michelle M Butler, Terry Bowlin, Bernd Meibohm, Mercedes Gonzalez-Juarrero, Anne J Lenaerts, Matthew Zimmerman, Richard E Lee, Gregory T Robertson\",\"doi\":\"10.1128/aac.01183-25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0118325\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01183-25\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01183-25","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

spectinamide作为实验性结核病治疗药物已经引起了人们的兴趣，因为它们的安全性和作为伙伴剂与已建立的小鼠方案联合使用时的有效性。由贝达喹啉、普雷托马奈和利奈唑胺组成的Nix-TB方案是推荐用于治疗广泛耐药前结核病的一种短期有效方案。然而，利奈唑胺与严重不良事件相关，限制了其使用。在这里，我们提供了比较利奈唑胺或spectinamide MBX-4888A锚定的Nix-TB方案的临床前数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.

Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.